Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ShangPharma
ShangPharma
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Bayer HealthCare and Johns Hopkins University to collaborate on new ophthalmic therapies
The partners will work jointly on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Design & Build
ShangPharma and Qidong Biopharma sign US$60m investment deal in China
Preclinical research facility and a state-of-the-art biologics manufacturing facility to be built in Qidong
Manufacturing
Mitchell Reff becomes Chief Biologics Officer at ShangPharma
He brings more than 30 years of reaearch experience to the position
Manufacturing
ShangPharma appoints Arthur Taveras as President and CSO
Taveras brings the experience of a 24-year career to the Chinese contract research organisation
Buyouts prove popular in China
Chinese pharma companies turning to private capital
You need to be a subscriber to read this article.
Click here
to find out more.
Finance
Picking up a good deal
This month Asia correspondent A Nair looks at why the emerging economies provide so many tempting takeover targets for Big Pharma
Research & Development
ShangPharma opens new plant to support Eli Lilly
Also signs a multi-year extension of its contract with the US firm
Subscribe now